Myriad Genetics (MYGN) and Lumea have signed an agreement to integrate Myriad’s advanced molecular diagnostic tests – Prolaris Prostate Cancer ...

This collaboration will streamline the ordering and delivery of molecular tests, enabling healthcare providers to electronically order and track Prolaris and MyRisk tests, with results delivered ...

Molecular genetic testing of asymptomatic children ... was already offering testing for MEFV mutations in UCLA's molecular diagnostic laboratory, was invited to join the group as a regular ...

The study objective is to provide current estimates of utilization/spending trends for molecular diagnostic and genetic testing for commercially insured, Medicare and Medicaid populations.

Myriad Genetics, Inc. is a molecular diagnostic company, which focuses on developing and marketing of novel predictive and personalized medicines and prognostic medicine tests. It operates through ...

Global in vitro diagnostics (IVD) market will reach $148,393.3 million by 2031, growing by 6.3% annually over 2021-2031. The global in vitro diagnostics (IVD) market encompasses a wide range of ...

Mainz Biomed N.V. (MYNZ), a molecular genetics diagnostic company, announced on Monday, that it has regained compliance with Nasdaq's ...

In a retrospective study of 265 patients with drug-resistant solid organ cancers, ‘Exacta AI’ provided at least seven therapy ...

(RTTNews) - Mainz Biomed N.V. (MYNZ), a molecular genetics diagnostic company, announced on Monday, that it has regained compliance with Nasdaq's continued listing requirements. The company ...

and MAINZ, Germany, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early ...

The University of Texas MD Anderson Cancer Center and Myriad Genetics ... Myriad's molecular residual disease (MRD) assay. This strategic alliance brings together the longstanding oncology ...